Table 1.
Nanoparticles studied as nano-drug carriers in designing of DSF
| Fabrication technique | Components | Particle Size(nm) | Z.P⃰ (mV) | %EE⃰, %D. L⃰ | Indication | Route of Administration | Cell line/Animal | Major outcome | Ref. | |
|---|---|---|---|---|---|---|---|---|---|---|
| Polymeric NPs | ||||||||||
| High-Pressure Homogenization Method | mPEG-PLA/PLA or mPEG-PCL/PCL,DSF | 100.5 ± 10.8 | – | 5.21 | Liver Cancer | i.v. | H22/ Male Sprague-Dawley (SD) rats |
-Improved the pharmacokinetic of DSF -Enhanced the tumour inhibition growth -Better drug loading and stability |
[36] | |
| Emulsion-Solvent Evaporation Method | PLGA, Polysorbate 80, DSF | 120 | – | 24 | Liver Cancer | – | Hep3B |
-Achieved sustained drug release patterns -Reduced dosage regimens -Improved anti-cancer efficacy of DSF-NPs |
[37] | |
| Emulsion-Solvent Evaporation Method | PLGA, PVA, DSF | 145.9 ± 5.0 | +36.2 ± 4.6 | 94 | Non-small cell lung Cancer | – | A549 |
-Improved tumour inhibition growth -Better loading capacity -Improved drug stability |
[38] | |
| Synthesized | LBA-PDA-PEG-DSF | 30.05 ± 0.42 | – | – | Metastatic ovarian Cancer | i.p. | SKOV-3/ Mice |
- stronger inhibitory effect as compared blanked NPs - Reduced toxicity |
[39] | |
| Nanoprecipitation Method | PGA-CisPt, DSF | 15.7 ± 1.3 | −9.4 ± 2.3 | 19.5 | Lung Cancer | i.v. | A549/ Balb/C nude mice |
-Improved the therapeutic efficacy of cisplatin -Reduced toxicity associated with cisplatin -Overcome drug induced resistance |
[40] | |
| Nanoprecipitation Method | PEG-PLGA/PCL, DSF | 91.8 ± 25.3 | – | 2.0 | Breast Cancer | i.v. | MCF-7/ Balb/C mice |
-High drug loading -Improved stability - preventing from rapid degradation |
[41] | |
| Nanoprecipitation Method | PLGA, PEG, PVA, DSF | 204 | – | – | Breast Cancer | i.v., i.p. | MCF-7 Female BALB/c mice |
-Extended the drug half-life -More potent effects as compared with raw drug |
[42] | |
| Emulsion Solvent Evaporation Technique | PLGA, mPEG-COOH, DSF | 81.74 ± 8.7 | −8.27 | 18.47, 92.1 | Brain Cancer | i.v. | T98G and DAOY/female athymic nude |
-Increased plasma half-life of DSF -Efficient penetration toward tumour inhibition growth |
[43] | |
| Nanoprecipitation Method | PLGA, PVA, DSF | 165 | – | 5.35 ± 0.03%, 58.85% | Breast Cancer | – | MCF-7 | - Provide better stability to drug molecules | [44] | |
| Emulsion-Solvent 1Evaporation Method | PLGA, PVA, DSF | 136.2 ± 6.2 | −21.7 ± 0.96 | 27.67 ± 3.47, 78.92 ± 2.16 | Liver Cancer | i.v. | HCC/nude mice |
-Better EE, DLC -In -vitro controlled release and improved half-life. |
[45] | |
| Dialysis Method | PCL, mPEG. DSF, DOX | 143.9 ± 2.1 | – | 1.02, 21.42 | Breast Cancer | i.v. | MCF-7 and MDA-MB-231/ female BALB/c mice | -Exhibited increased cellular uptake by tumour cells, an improved drug synergistic effect. | [46] | |
| Synthesized | Cu (DCC), DSF. mPEG PEC | 200 | −25 | 4.55% | i.v. | A549 |
-Excellent stability -Improved anti-cancer efficacy |
[47] | ||
| Micelles | ||||||||||
| Emulsification-Solvent Diffusion Method | mPEG5k-b-PLGA2k/PCL3.4 k/MCT, DSF | 86.4 ± 13.2 | −24.5 ± 1.5 | 5.90 | Liver Cancer | i.v. | H22/ Kunming mice |
-Improved plasma stability of DSF -More potent as compared with free drug |
[48] | |
| Ring-Opening Polymerization | PEG-b-PLL, PTX, DSF | 138 ± 8.5 | −12.4 ± 1.3 | 2.15 ± 0.5 | 89.3 ± 1 | Breast Cancer | – | MCF-7 |
-Reverse MDR to breast cancer -Achieved synergistic effect |
[49] |
| Synthesized | Poly (styrenecomaleic anhydride) (SMA), DSF | 80 | −21.9 | 7.5,75.4 | Breast Cancer | i.v. | 4 T1/female BABL/c mice |
-Improve the targeted intracellular delivery of DSF -Highly accumulation in tumour site |
[29] | |
| Synthesized | SMA, DSF, PTX |
88.58± 4.12 |
−22.8 | 5 | Breast Cancer | i.v. | MCF-7/female BALB/c nude |
-High drug loading -Improved cellular interlization |
[30] | |
| Nanocrystals | ||||||||||
| Anti-solvent Precipitation Method | Beta lactoglobulin, DSF, PTX | 160 | −24 | 36.23 ± 0.9, 96.6 ± 0.24 | Lung Cancer | – | A549 |
-Efficient MDR Reversal -Enhanced Apoptosis |
[50] | |
| Anti-solvent Precipitation-Ultrasonication Method | Beta lactoglobulin, DSF, PTX | 160 | −24 | 36, 7 | Lung Cancer | i.v. | A549 cells/ female BALB/c nude mice | -PTX-DSF Ns improve the MDR-reversal | [51] | |
| Microparticles | ||||||||||
| Emulsion Solvent Evaporation Method | PLGA, PVA, DSF | 47.83 ± 13.21 μm | −14.9 ± 4.7 | 4.09 ± 0.11, 81.84 ± 2.3 | Non-small-cell lung Cancer | – | A549, HCC827 cells |
-Efficient anti-proliferation -Improved anti-tumour efficiency |
[52] | |
| Lipid based Nanocarriers | ||||||||||
| Phase-Inversion Method | HS-PEG1k-TATp, DSF | 93.7 | −40.13 ± 2.83 | 3.59 ± 0.36 | Liver Cancer | i.v. | Hep G2 cells/BALB/cA nude mice |
-Better stability -Better tumour internalization and increased cytotoxicity |
[53] | |
| Emulsification Ultrasonication Method | TPGS. lecithin, PC, 98%), tween80, Labrafac, DSF | 188.6 ± 1.5 | −27.91 ± 2.5 | 80.7 ± 2.68 | Breast Cancer | i.v. | MCF-7/female BALB/c mic |
-Improve the drug loading, release, stability, -Improve the overall anti-cancer effect of DSF both in-vitro and in vivo. |
[54] | |